Annibale Bruno, Lahner Edith, Fave Gianfranco Delle
Department of Digestive and Liver Disease, University Sapienza, Medical School, Ospedale Sant'Andrea, Via di Grottarossa 1035, 00189 Rome, Italy.
Curr Gastroenterol Rep. 2011 Dec;13(6):518-24. doi: 10.1007/s11894-011-0225-5.
Pernicious anemia is a macrocytic anemia due to cobalamin deficiency, which is the result of intrinsic factor deficiency. Pernicious anemia is associated with atrophic body gastritis, whose diagnostic criteria are based on the histologic evidence of gastric body atrophy associated with hypochlorhydria. Serological markers suggesting the presence of oxyntic mucosa damage are increased levels of fasting gastrin and decreased levels of Pepsinogen I. Without the now obsolete Schilling's test, intrinsic factor deficiency may not be proven, and gastric intrinsic factor output after pentagastric stimulation has been proposed. Intrinsic factor autoantibodies are useful surrogate markers of pernicious anemia. The management of patients with pernicious anemia should focus on the life-long replacement treatment with cobalamin and the monitoring to early diagnose an eventual onset of iron deficiency. Moreover, these patients should be advised about possible gastrointestinal long-term consequences, such as gastric cancer and carcinoids.
恶性贫血是一种由于钴胺素缺乏导致的大细胞性贫血,而钴胺素缺乏是内因子缺乏的结果。恶性贫血与萎缩性胃体胃炎相关,其诊断标准基于胃体萎缩伴胃酸过少的组织学证据。提示胃泌酸黏膜损伤的血清学标志物是空腹胃泌素水平升高和胃蛋白酶原I水平降低。在现已过时的希林试验无法进行的情况下,可能无法证实内因子缺乏,因此有人提出了五肽胃泌素刺激后胃内因子分泌量的检测方法。内因子自身抗体是恶性贫血有用的替代标志物。恶性贫血患者的管理应侧重于终身补充钴胺素治疗以及监测以便早期诊断最终可能出现的缺铁情况。此外,还应告知这些患者可能出现的胃肠道长期后果,如胃癌和类癌。